ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2614

Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus

April Jorge1, Leo Lu2, Yuqing Zhang3, Sharan K. Rai4, Lucy H. Young5, Ronald B. Melles6, Michael F. Marmor7, Karen H. Costenbader8, Rosalind Ramsey-Goldman9, S. Sam Lim10, John M. Esdaile11, Ann E. Clarke12, Murray Urowitz13, Anca Askanase14, Cynthia Aranow15, Michelle Petri16 and Hyon K. Choi4, 1Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Department of Ophthalmology,, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, 6Department of Ophthalmology, Kaiser Permanente, Redwood City, CA, 7Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, 8Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 9FSM, Northwestern University, Chicago, IL, 10Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 11Arthritis Research Canada, Richmond, BC, Canada, 12Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 13Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 14Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 15Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, 16Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Hydroxychloroquine, prescribing trends and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 7, 2017

Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

<>Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone of systemic lupus erythematosus (SLE) care. The major long-term adverse event risk is vision-threatening toxic retinopathy. The 2012 EULAR, 2009 Royal College of Ophthalmology, and 2011 American Academy of Ophthalmology (AAO) guidelines recommended a maximum dosing of the lower of 6.5mg/kg/day of ideal body weight (IBW) or 400 mg daily to minimize the risk of retinopathy, whereas the 2016 AAO guidelines revised this to a maximum of 5mg/kg/day of actual body weight (ABW). We assessed the trend of HCQ prescribing patterns for treating SLE in relation to these dosing guidelines over the past two decades in a general population context. Furthermore, we examined associations with purported risk factors of HCQ retinopathy.

Methods: Using a United Kingdom general population database, we conducted an incident user study of adult SLE patients, identified by Read codes, who initiated HCQ between January 1, 1996 and December 31, 2015. We examined the secular trend of the proportion of initial prescribed HCQ doses exceeding 6.5mg/kg/day IBW as well as 5mg/kg/day ABW and assessed whether excess doses according to these guidelines varied by age, sex, body mass index (BMI; lean, overweight, and obese), and chronic kidney disease (CKD; defined by a eGFR <60). 

 

Results: Of 2741 SLE patients who initiated HCQ over this 20-year period, 36.2% of the prescribed doses were > 6.5mg/kg/day IBW, and 38.12% were > 5mg/kg/day ABW. There was no significant change in the rate of initial excess dosing over time for either dose cut-off (p for trends=0.09 and 0.25, respectively) (Table 1). Women had an increased risk of excess initial dosing compared with men, with OR=12.28 (95% CI, 7.46-20.23) for IBW and 2.00 (95% CI, 1.50- 2.66) for ABW dose recommendations. Obesity was associated with a lower risk of excess HCQ dosing using ABW (OR 0.14 for obese vs. lean (95% CI, 0.10-0.18), and a higher risk of excess dosing using IBW (OR 1.30 [95% CI, 1.06-1.59]). Age had no effect on the risk of excess HCQ dosing according to either recommendation (OR 1.11; 95% CI, 0.93-1.32 for IBW, and OR=1.07, 95% CI, 0.89-1.27 for ABW). For the subgroup with available eGFR data (n=657), CKD was associated with an increased risk of excess dosing per ABW (OR 1.85, 95% CI, 1.02-3.37) after adjusting for BMI.

 

Conclusion: In this general population-based study, over one-third of SLE patients were initiated on HCQ doses exceeding both dosing guidelines, and these rates have not changed over the past two decades. This rate of excess dosing is strikingly higher among women. Obesity posed opposing risk of excess dosing between the two weight-based dosing guidelines. Furthermore, excess dosing is also higher amongst CKD patients per the recent ABW-based guidelines. These findings highlight the potential need to improve excess HCQ dosing, and call for unifying, robust, and evidence-based recommendations.


Disclosure: A. Jorge, None; L. Lu, None; Y. Zhang, None; S. K. Rai, None; L. H. Young, None; R. B. Melles, None; M. F. Marmor, None; K. H. Costenbader, None; R. Ramsey-Goldman, None; S. S. Lim, None; J. M. Esdaile, None; A. E. Clarke, UCB, 2; M. Urowitz, UCB, 2; A. Askanase, Exagen, 2; C. Aranow, None; M. Petri, Anthera Inc, 5,GlaxoSmithKline, 5,EMD Serono, 5,Eli Lilly and Company, 5,Bristol Meyer Squibb, 5,Amgen, 5,United Rheumatology, 5,Global Academy, 5,Exagen, 2; H. K. Choi, Selecta, Horizon, 5,AstraZeneca, 2.

To cite this abstract in AMA style:

Jorge A, Lu L, Zhang Y, Rai SK, Young LH, Melles RB, Marmor MF, Costenbader KH, Ramsey-Goldman R, Lim SS, Esdaile JM, Clarke AE, Urowitz M, Askanase A, Aranow C, Petri M, Choi HK. Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/hydroxychloroquine-initiation-dosing-trends-and-predictors-in-systemic-lupus-erythematosus/. Accessed January 19, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hydroxychloroquine-initiation-dosing-trends-and-predictors-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.